MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE: ANRO), currently trading at $3.11 and down nearly 26% over the past week, has announced the continuation of its Phase 2b clinical trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback